Flurbiprofen-loaded stealth liposomes: Studies on the development, characterization, pharmacokinetics, and biodistribution

Journal of Young Pharmacists

Volumn 4, Issue 4, 2012, Pages 209-219

  Begum, M Y ^a   Abbulu, K ^b   Sudhakar, M ^a  

^a Malla Reddy College of Pharmacy ^*  (India)

^b Malla Reddy Institute of Pharmaceutical Sciences ^*  (India)

Author keywords

DSPC; flurbiprofen; in vitro; in vivo; PE 18:0 18:0 PEG 2000; stability

Indexed keywords

FLURBIPROFEN; LIPOSOME; MACROGOL 2000; STEALTH LIPOSOME; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PAW EDEMA; PERCENTAGE ENCAPSULATION EFFICIENCY; PHARMACEUTICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT; ZETA POTENTIAL;

EID: 84872146022     PISSN: 09751483     EISSN: 09751505     Source Type: Journal    
DOI: 10.4103/0975-1483.104364     Document Type: Article

References (33)

1. Bangam AD, Standish MM, Miller N. Cation permeability of phospholipid model membranes: Effect of narcotics. Nature 1965;208:1295-7.
2. Panwar P, Pandey B, Lakhera PC, Sing KP. Preparation, characterization and in vitro release study of albendazole-encapsulated nano size liposomes. Int J Nanomedicine 2010;5:101-8.
3. Immordino ML, Dosio F, Cattel L. Stealth liposomes: Review of the basic science, rationale and clinical applications existing and potential. Int J Nanomedicine 2006;1:297-315.
4. Allen TM. Toxicity of drug carriers to the mononuclear phagocyte system. Adv Drug Del Rev 1988;2:55-67.
5. Mauk MR, Gamble RE. Stability of lipid vesicles in tissues of the mouse. A gamma-ray perturbed angular correlation study. Proc Natl Acad Sci USA 1979;76:765-9.
6. Abra RM, Hunt CA. Liposome distribution in vivo: III Dose and vesicle-size effects. Biochim Biophys Acta 1981;666:493-503.
7. Kunie V, Maeda F, Harashima H, Kiwada H. Saturable, non-Michaelis-Menten uptake of liposomes by the reticuloendothelial system. J Pharm Pharmacol 1990;43:162-6.
8. Allen TM, Hansen C. Pharmacokinetics of stealth and non-stealth liposomes: Effect of dose. Biochim Biophys Acta 1991;1068:133-41.
9. Gregoriadis G, Senior J. The phospholipid component of small unilamellar liposomes controls the rate of clearance of entrapped solutes from the circulation. FEBS Lett 1980;119:43-6.
10. Allen TM, Cleland LG. Serum-induced leakage of liposomes contents. Biochim Biophys Acta 1980;597:410-26.
11. Scherphof GL, Damen J, Wilschut J. Interactions of liposomes with plasma proteins. In: Gregoriadis G, editor. Liposome technology. Vol. 3. Boca Raton FL: CRC Press; 1984. p. 205-24.
12. Danilo DL. Liposomes. Sci Med 1996;3:34-43.
13. Allen TM, Chonn A. Large unilamellar liposome with low uptake by the reticuloendothelial system. FEBS Lett 1987;223:42-6.
14. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A 1988;85:6949-53.
15. Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: Factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta 1989;981:27-35.
16. Allen TM, Ryan JL, Papahadjopoulos D. Gangliosides reduce leakage of aqueous space markers from liposomes in the presence of human plasma. Biochim Biophys Acta 1985;818:205-10.
17. Orlu M, Cevher E, Araman A. Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges. Int J Pharm 2006;318:103-17.
18. Brogden RN, Heel RC, Speight TM, Avery GC. Flurbiprofen: A review of its pharmacological properties and therapeutic use in rheumatic diseases. Drugs 1979;18:417-38.
19. Charoo NA, Shamsher AA, Kohli K, Pillai K, Rahman Z. Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. Colloids Surf B Biointerfaces 2008;65:300-7.
20. Cardoe N, Risdall JJ, Glass RC. Serum concentrations of flurbiprofen in rheumatoid patients receiving flurbiprofen over long periods of time. Curr Med Res Opin 1977;5:21-5.
21. Begum MY, Abbulu K, Sudhakar M. Design and evaluation of flurbiprofen Liposomes. J Pharm Res 2011;4:653-5.
22. Umrethia M, Ghosh PK, Majithya R, Murthy RS. 6-Mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity. Cancer Invest 2007;25:117-23.
23. Ramana MV, Choudhary AD. An approach to minimize pseudomembranous colitis caused by clindamycin through liposomal formulation. Indian J Pharm Sci 2007;69:390-3.
24. Hathout RM, Mansour S, Mortada ND, Guinedi AS. Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies. AAPS PharmSciTech 2007;8:E1-12.
25. Bonepally CR, Challa SR, Yellu NR, Akkaladevi M, Aukunuru JV. Preparation and characterization of piperine multilamellar vesicular liposomes intended for testing anticonvulsant activity in rats. Indian Drugs 2007;44:458-65.
26. Kumar R, Katare OP. Tamoxifen in topical liposomes: Development, characterization and in vitro evaluation. J Pharm Pharm Sci 2004;7:252-9.
27. Buddhadev L, Biswajit M. Tamoxifen citrate encapsulated sustained release liposomes: Preparation and evaluation of physico chemical properties. Sci Pharm 2010;76:507-15.
28. Rathode S, Deshpande SG. Design and evaluation of liposomal formulation of pilocarpine nitrate. Indian J Pharm Sci 2010;72:155-60.
29. Nasr M, Mansour S, Mortada ND, El Shamy AA. Lipospheres as carriers for topical delivery of aceclofenac: Preparation, characterization and in vivo evaluation. AAPS PharmSciTech 2008;9:154-62.
30. Ustündag Okur N, Apaydin S, Karabay Yavasoglu NÜ, Yavasoglu A, Karasulu HY. Evaluation of skin permeation and anti-inflammatory and analgesic effects of new naproxen microemulsion formulations. Int J Pharm 2011;416:136-44.
31. Graeme NL, Fabry E, Sigg EB. Myocardial adjuant periarthritis in rodents and its modification by anti-inflammatory agents. J Pharmacol Exp Ther 1966;153:373-80.
32. Taro O, Yoshimasa I, Masahiro I, Hidehiko A. A pharmacokinetic model for the percutaneous absorption of indomethacin and the prediction of drug disposition kinetics. J Pharm Sci 1989;78:319-23.
33. Mohammed AR, Weston N, Coombes AG, Fitzgerald M, Perrie Y. Liposome formulation of poorly water soluble drugs: Optimization of drug loading and ESEM analysis of stability. Int J Pharm 2004;285:23-34.